Table 3 Summary of reported cases of COVID-19-associated extra-pulmonary Aspergillus infections
Authors | Patient age | Patient gender | Comorbidities | Interval between COVID-19 and Aspergillus infection | Infection type | Medical treatment | Outcome |
|---|---|---|---|---|---|---|---|
De Villiers De La Noue et al. [25] | 60 | Male | None | 35 days | Brain abscess | Voriconazole | Recovery |
Makhdoomi et al. [43] | 85 | Male | None | 7 months | Spinal abscess | Liposomal Amphotericin B | Recovery |
Hosseinikargar et al. [44] | 38 | Male | Acute myeloid leukemia | Simultaneous | Rhinosinusitis | Fluconazole, Amphotericin B | Death |
Hakamifard et al. [45] | 35 | Male | None | Simultaneous | Brain abscess | Voriconazole, Liposomal Amphotericin B | Death |
Sahu et al. [46] | N/A | N/A | N/A | 1–31 days | Endophtalmitis | Vitrectomy | Vision loss |